Tuesday 17 November 2026 The business of healthcare in India, the UK and the Gulf
The Healthcare Daily
Get The Handover

Guide

Revised Schedule M: a guide to India's GMP rules for drugmakers in 2026

India's revised drug manufacturing rules now apply to every licensed maker. Here is what changed, who had which deadline, how enforcement has worked and what to watch.

Follow on Google News (opens in a new tab)
Technician in protective clothing working on tablet production in a sterile pharmaceutical plant
Representative photograph: a technician in protective clothing on a tablet production line. Getty Images for Unsplash+.

What you need to know

  • Revised Schedule M was notified by G.S.R. 922(E) on 28 December 2023 and, the health ministry said, took effect for manufacturers with turnover above Rs 250 crore on 28 June 2024.
  • Smaller firms that applied in Form A within three months of 11 February 2025, under G.S.R. 127(E), had until 31 December 2025.
  • The revision adds a pharmaceutical quality system, quality risk management, product quality reviews, change control, recall and supplier audit requirements.
  • The DCGI told states on 7 November 2025 to inspect units, with 1 January 2026 as the effective date for those granted more time.
  • The DCGI said in July 2026 that regulators had carried out more than 960 risk-based inspections and audits since late 2022, about 860 of which led to enforcement, Reuters reported.

Schedule M is the part of India’s Drugs Rules, 1945, that sets the good manufacturing practices (GMP) every licensed medicine maker must follow, and its revised text has changed what inspectors expect to find in a factory. Union Health Minister J P Nadda told the Rajya Sabha in July 2025 that manufacturers must follow licence conditions, including GMP under the Drugs Rules, PTI reported. For plant owners, quality heads, contract givers, buyers and investors the questions are practical: what the revised Schedule M requires, which deadline applied to whom, what has happened since the last extension ran out, and what support exists. This guide answers them as of November 2026.

It draws on the notifications listed on the gazette notifications page of the Central Drugs Standard Control Organisation (CDSCO), answers given in Parliament, and statements by the Drugs Controller General of India (DCGI). Where a figure comes from a newspaper rather than an official document, the text says so.

What Schedule M is and who it applies to

Schedule M carries the title “Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products”, wording that G.S.R. 922(E) also wrote into rules 74, 76 and 78 of the Drugs Rules. A Lok Sabha answer of 29 November 2024, given in reply to a question about firms with turnover below Rs 250 crore, said manufacturers must comply with Schedule M of the Drugs Rules, 1945. In other words, size decides the deadline, not whether the rules apply.

The revision took more than five years. The Ministry of Health and Family Welfare published a draft, G.S.R. 999(E), on 5 October 2018, considered objections, consulted the Drugs Technical Advisory Board and issued the final notification, G.S.R. 922(E), on 28 December 2023, its preamble records. CDSCO’s gazette list shows a corrigendum, G.S.R. 666(E), dated 25 October 2024.

Enforcement is shared between the centre and the states. CDSCO, headed by the DCGI, runs risk-based inspections with state regulators, and in November 2025 the DCGI told every state and Union Territory drug controller to inspect units for compliance. The DCGI told a regulatory conclave in New Delhi in July 2026 that regulators oversee more than 10,000 manufacturing facilities, Reuters reported. Industry experts quoted by Business Standard in February 2025 put the number of pharmaceutical units at about 10,500, of which about 8,500 are micro, small and medium enterprises (MSMEs).

One number in the rules matters more than any other: Rs 250 crore of annual turnover. It splits manufacturers into “large” and “small and medium” for the purpose of deadlines, and it decided who could ask for more time. Reuters also tied the wider quality drive to scrutiny of India after Indian-made cough syrups were linked to child deaths in Gambia, Uzbekistan and Cameroon.

What revised Schedule M changed

Law firm JSA noted in a January 2024 analysis that the old Schedule M covered GMP practices but set no specific requirements for the products themselves. The revised schedule moves Indian rules towards a full quality management system. The notification itself, a June 2024 presentation by a CDSCO joint drugs controller and the JSA analysis list these new or expanded elements:

  • a pharmaceutical quality system (PQS), with senior management ultimately responsible for failures;
  • quality risk management (QRM), a systematic process for assessing, controlling, communicating and reviewing risks;
  • product quality reviews covering starting and packaging materials, failed batches, process and analytical method changes, in-process controls, and quality-related returns, recalls and complaints;
  • qualification and validation, with detailed requirements for equipment as well as processes;
  • a system to recall defective products, and a new section on complaints and adverse reactions;
  • formal change control;
  • self-inspection, quality audits, and audit and approval of suppliers;
  • new provisions on production under a loan licence or contract;
  • stability studies and validation of GMP-related computerised systems;
  • specific requirements for hazardous products, biological products, radiopharmaceuticals and phytopharmaceuticals.

The English text of G.S.R. 922(E) opens Part I with the pharmaceutical quality system and quality risk management, followed by sections on good manufacturing practices for pharmaceutical products, sanitation and hygiene, qualification and validation, complaints and adverse reaction, product recalls, change control, production under loan licence or contract and contract analysis, self-inspection, quality audits and suppliers’ audits, personnel, premises, equipment and materials, and later documentation, good practices in production and quality control, and computerised systems.

The product quality review must include a review of the stability monitoring programme. Parts II to XIII then add specific requirements for sterile products, products containing hazardous substances, biological products, radiopharmaceuticals, phytopharmaceuticals, investigational products for clinical trials, oral solid dosage forms, oral liquids, topical products, metered-dose inhalers and active pharmaceutical ingredients, and list recommended plant and equipment.

The text settles points that buyers often ask about. The licensing authorities must be informed if a manufacturer is considering action following faulty manufacture, product deterioration, a suspect product or any other serious quality problem (section 6.10). Self-inspection must take place at least once a year (section 10.4). Arrangements for production under loan licence or contract, including technology transfer, must accord with the product licence, and the contract must let the loan licensee or contract giver audit the contract acceptor’s facilities (section 9).

Two later circulars show the schedule being applied. The CDSCO circulars page lists one dated 7 August 2024 titled “Implementation of Schedule M and WHO Technical Report Series”, and another dated 3 June 2026 on implementing a pharmacovigilance system “as per the requirement of Schedule M”.

A worker operates machinery in a cleanroom, a representative image for this guide to revised Schedule M
Representative photograph: a worker operating machinery in a cleanroom. Mina Rad on Unsplash.

Schedule M deadlines for large firms and MSMEs

The original notification gave large manufacturers six months and small and medium manufacturers twelve months from publication, as a Lok Sabha answer of 9 February 2024 set out. In a statement on 12 February 2025 the health ministry said the revised requirements had been implemented for large manufacturers with effect from 28 June 2024; a Rajya Sabha reply published by the Press Information Bureau on 12 August 2025 gave the date as 29 June 2024.

For smaller firms the ministry first published a draft, G.S.R. 10(E), on 4 January 2025, then notified the final terms in G.S.R. 127(E) of 11 February 2025, the Drugs Amendment Rules, 2025. Firms with turnover below Rs 250 crore could apply to the Central Licence Approving Authority in Form A within three months of publication, with a plan of upgradation, and have their timeline extended to 31 December 2025.

Group Turnover Timeline in the rules Position as of November 2026
Large manufacturers Above Rs 250 crore Six months from publication on 28 December 2023 In force since 28 June 2024, the health ministry said
Small and medium manufacturers that applied in Form A Less than Rs 250 crore Twelve months, extended to 31 December 2025 Effective from 1 January 2026, according to the DCGI’s November 2025 letter
Small and medium manufacturers that did not apply Rs 250 crore or less Twelve months from publication Already applicable; states told to inspect and act immediately

The wording differs slightly between documents. G.S.R. 922(E) and the ministry’s February 2025 statement define small and medium manufacturers as those with turnover of Rs 250 crore or less, while the extension proviso in G.S.R. 127(E) refers to turnover “less than two hundred and fifty crores”. Form A asked applicants to report turnover for April 2023 to March 2024.

As of November 2026, CDSCO’s gazette list shows no Schedule M notification after G.S.R. 127(E). In January 2026 Medical Dialogues, citing The Economic Times, reported that the ministry was weighing conditional extensions for firms that had shown genuine intent and progress, and a later Medical Dialogues report said Mr Nadda met representatives of Laghu Udyog Bharti, a body representing small and micro enterprises, on 10 and 16 January. No further extension has appeared in the gazette list since.

How the extension worked: Form A and the ONDLS portal

Form A, annexed to G.S.R. 127(E), shows what the regulator wanted from each applicant. The steps were:

  1. Give the manufacturer’s name and address, turnover for April 2023 to March 2024, and every licence held, with number and validity.
  2. State the sections held and whether the site has a WHO-GMP certificate or a Certificate of Pharmaceutical Product (CoPP), with validity.
  3. Submit a section-wise gap analysis covering plant, equipment, laboratory equipment, the HVAC system, utilities, technical staff and documentation.
  4. Set out a plan matching each gap, starting on or before 31 March 2025.
  5. Request time not beyond 31 December 2025 and justify it.
  6. Sign an undertaking, by a director, partner, proprietor or authorised signatory, that the gap analysis was complete and that upgrading would start within three months of the application.

In March 2025 CDSCO told applicants to file only online, through the Online National Drugs Licensing System (ONDLS), Business Standard reported. The circulars page lists the instruction, “On line application for extension of time to comply with revised Sch M on ONDLS portal”, under 24 March 2025. The paper also reported that the health ministry would audit the facilities after three months and act where committed upgrades were not carried out.

Take-up appears to have been limited. Business Standard reported on 29 December 2025 that only about 1,700, or 26% of an estimated 6,500 MSME manufacturers required to meet the revised norms, had submitted upgradation plans. The paper gave no source for that figure; the rest of its report relied on unnamed ministry sources and people aware of the matter. A survey by Laghu Udyog Bharti, reported by Medical Dialogues on 19 January 2026, found that around 25% of pharmaceutical units were seeking a further extension. Neither figure is an official count, and none of the official pages cited in this guide gives one.

Inspections and enforcement since 2022

Risk-based inspections began in December 2022, run by CDSCO with state regulatory authorities, Mr Nadda told the Rajya Sabha on 22 July 2025, according to PTI. Firms were picked on risk factors including the number of drugs declared not of standard quality, complaints and the criticality of the product. The Minister of State, Anupriya Patel, gave the same totals in a Rajya Sabha reply published on 12 August 2025. CDSCO issued guidelines for risk-based inspections of manufacturing facilities in a circular dated 27 March 2024.

Reported Source Inspections Outcome
9 February 2024 Lok Sabha answer 275 premises More than 250 actions, including show cause notices, stop production orders, suspensions and cancellations
June 2024 CDSCO presentation About 375 manufacturing sites and 200 testing sites 67 manufacturing permissions cancelled and 50 suspended; 1 testing facility cancelled and 10 suspended
July and August 2025 Rajya Sabha replies, reported by PTI on 22 July and published by PIB on 12 August 905 units since December 2022 694 actions
30 July 2026 DCGI at the Global Drug Regulatory Conclave, reported by Reuters More than 960 inspections and audits since late 2022 About 860 led to enforcement, about 90% of high-risk sites inspected

The actions named in the July and August 2025 replies run from stop production and stop testing orders to licence suspension or cancellation, warning letters and show cause notices, depending on severity. DCGI Rajeev Raghuvanshi said in July 2026 that regulators identify gaps, inform manufacturers and give them time according to the type and severity of the problem, Reuters reported.

The firmest instruction came on 7 November 2025. The DCGI wrote to all state and Union Territory drug controllers calling Schedule M compliance a top priority, PTI reported. For units that had applied for the extension, states were to plan inspections, with an effective date of 1 January 2026; for units that had not applied, inspection and action were to start at once. States were told to take strict action against non-compliant units under the Drugs and Cosmetics Act and its rules, and to send monthly reports on what inspectors found and what action followed.

PTI connected the directive with reported child deaths in Madhya Pradesh allegedly caused by cough syrups contaminated with diethylene glycol.

A laboratory workbench with a microscope and analytical equipment in a bright room
Representative photograph: a laboratory workbench with a microscope and analytical equipment. Trnava University on Unsplash.

A Schedule M compliance checklist for manufacturers

The checklist below follows the elements that the rules, Form A and CDSCO’s own presentation name. It is a planning aid for management teams, not a substitute for the full text of the schedule.

  • Quality system: a documented PQS with senior management responsibility, and a QRM process covering assessment, control, communication and review of risk.
  • Product quality reviews: a periodic review for each product, drawing on raw material data, failed batches, changes, in-process controls, returns, recalls and complaints.
  • Qualification and validation: equipment qualification as well as process validation, and validation of GMP-related computerised systems.
  • Complaints, adverse reactions and recalls: written procedures, a recall system and a pharmacovigilance system, the subject of CDSCO’s June 2026 circular.
  • Change control: a formal system for approving and recording changes.
  • Contract work: written agreements setting out the duties of contract giver and contract acceptor for loan licence and contract manufacturing and analysis.
  • Audits: self-inspection, quality audits, and supplier audit and approval.
  • Stability: stability studies, including a stability monitoring programme.
  • Plant and people: the Form A gap areas of HVAC, utilities, laboratory equipment, technical staff and documentation.
  • Product-specific requirements: the separate provisions for hazardous, biological, radiopharmaceutical and phytopharmaceutical products, where relevant.

Documentation runs through the whole regime. Form A asked for a section-wise gap analysis, and the Department of Pharmaceuticals ties payments under its upgrade subsidy to certificates: under an office memorandum of 21 March 2026, an applicant can claim the first instalment with either a revised Schedule M or a WHO-GMP certificate and must submit the other with the claim for the second.

Money and support: RPTUAS and WHO-GMP

The Department of Pharmaceuticals runs the Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) to help existing units reach revised Schedule M and WHO-GMP standards. In a Lok Sabha answer on 6 December 2024, Minister of State Anupriya Patel said it is open to existing manufacturing units with average annual turnover of less than Rs 500 crore over the last three years.

The incentive is paid by reimbursement, at 10% to 20% of eligible spending depending on turnover, up to Rs 2 crore per unit, according to that answer. Older scheme documents give a lower cap. The department’s revamp of 11 March 2024 set the rate at 20% for units with turnover from Rs 1 crore to under Rs 50 crore, 15% from Rs 50 crore to under Rs 250 crore and 10% from Rs 250 crore to under Rs 500 crore, subject to a maximum of Rs 1 crore.

A corrigendum of 17 September 2024 raised the maximum to Rs 2 crore and added production equipment to the eligible items, which also cover utilities, clean rooms, testing laboratories and stability chambers, effluent treatment and waste management, and consultation or certification costs. At the date of the Lok Sabha answer, 62 projects had been sanctioned Rs 59.55 crore, 58 of them MSMEs, and nothing had yet been disbursed. Later sanction and disbursement figures are not published in the official sources cited here.

WHO-GMP certification sits alongside the revised schedule. Business Standard reported in February 2025, and again in December 2025, that about 2,000 MSME units held WHO-GMP certification. During 2025 CDSCO moved grants of WHO-GMP certificates and CoPPs to the ONDLS portal, according to circulars dated 25 June 2025 and 26 September 2025 on its circulars page.

What revised Schedule M means for MSMEs, buyers and investors

For MSME manufacturers the issue is capital. An executive at an MSME drug maker told Business Standard in December 2025 that every form of upgrade needs capital of at least Rs 2 crore, and that many units operate from single facilities in small premises. Because RPTUAS reimburses spending after the work is done, units still have to finance upgrades first.

For buyers, including hospital groups, distributors and brand owners that source from contract manufacturers, the revised rules add documents worth asking for: evidence of the quality system and product quality reviews, recall and pharmacovigilance procedures, the supplier’s inspection history, and any revised Schedule M, WHO-GMP or CoPP certificates. The new provisions on production under a loan licence or contract mean the brand owner and the factory each carry defined duties.

For investors and lenders, enforcement data now belongs in diligence. The DCGI’s July 2026 figures, as reported by Reuters, point to action at about 90% of high-risk sites inspected. Listed companies also report foreign inspections: The Healthcare Daily has covered a single US FDA observation at Rubicon Research’s Satara site and two observations at Dr. Reddy’s FTO-11 plant. Testing capacity has drawn buyers too, as in Cotecna’s purchase of the Hyderabad testing laboratory Energon Labs.

For exporters, the direction of travel is towards international norms. Business Standard said in February 2025 that the revision was meant to bring compliance on a par with global standards, especially those of the WHO, and a summary published by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) says Schedule M was revised to harmonise it with WHO guidelines. Form A itself asked whether an applicant already held a WHO-GMP certificate or CoPP, which shows how closely the regulator links the two.

Small pink tablets tumbling across the surface of a production machine
Representative photograph: tablets moving across the surface of a production machine. Sulyok Img on Unsplash.

What to watch next

  • Any further relaxation. Ministry talks reported in January 2026 had not, as of November 2026, produced a new Schedule M notification in CDSCO’s gazette list.
  • State enforcement. The November 2025 letter requires monthly state reports on inspections and actions, which gives states a regular channel for reporting suspensions and cancellations.
  • Pharmacovigilance. CDSCO’s June 2026 circular puts pharmacovigilance systems on the compliance list alongside plant upgrades.
  • Subsidy uptake. The March 2026 change lets RPTUAS applicants claim the first instalment with a WHO-GMP certificate, so later sanction and disbursement data will show whether more units draw on the scheme.
  • Digital inspection. The DCGI said in July 2026 that more than 99% of CDSCO processes are digitised and that it is piloting AI tools for pre-inspection checklists, recommending regulatory action, drafting reports and classifying risk, Reuters reported.
  • Wider rule changes. CDSCO’s gazette list for 2026 includes G.S.R. 706(E) of 30 July 2026 on debarment of applicants who submit misleading or fabricated documents, and G.S.R. 951(E) of 28 October 2026 on rationalisation of shelf life under Rule 31 of the Drugs Rules.

The Healthcare Daily follows these changes on The Tracker and in its pharma and life sciences coverage.

Questions readers ask

What is revised Schedule M?

It is the revised set of good manufacturing practice requirements in Schedule M of India's Drugs Rules, 1945, notified by G.S.R. 922(E) on 28 December 2023. It adds a pharmaceutical quality system, quality risk management, product quality reviews, change control, recall systems, supplier audits, stability studies and validation of computerised systems, plus specific parts for hazardous, biological, radiopharmaceutical and phytopharmaceutical products.

When did revised Schedule M apply to large manufacturers?

Manufacturers with turnover above Rs 250 crore had six months from publication. The health ministry said in February 2025 that the revised requirements took effect for them on 28 June 2024. Smaller manufacturers had twelve months, with an option to seek more time.

What was the Schedule M deadline for MSMEs?

Small and medium manufacturers originally had twelve months from 28 December 2023. G.S.R. 127(E) of 11 February 2025 let firms with turnover below Rs 250 crore apply in Form A within three months, with an upgrade plan, and extended their timeline to 31 December 2025. The DCGI treated 1 January 2026 as their effective date.

Has the Schedule M deadline been extended beyond December 2025?

As of November 2026, CDSCO's list of gazette notifications shows no Schedule M notification after G.S.R. 127(E). Reports in January 2026 said the health ministry was weighing conditional extensions for firms showing progress, but no further extension has appeared in the gazette list.

What is Form A under revised Schedule M?

Form A was the application for more time under G.S.R. 127(E). It asked for turnover for April 2023 to March 2024, licence details, any WHO-GMP certificate or CoPP, a section-wise gap analysis, a plan starting by 31 March 2025, the time needed up to 31 December 2025, and a signed undertaking to start upgrading within three months.

What happens to drug units that fail Schedule M inspections?

Actions named by the health minister in July 2025 range from stop production and stop testing orders to licence suspension or cancellation, warning letters and show cause notices, depending on severity. The DCGI's November 2025 letter told states to take strict action against non-compliant units under the Drugs and Cosmetics Act.

Is there government support for Schedule M upgrades?

The Department of Pharmaceuticals runs RPTUAS for existing units with average turnover under Rs 500 crore. Under its guidelines as revised on 17 September 2024, it reimburses 20%, 15% or 10% of eligible investment depending on turnover, up to Rs 2 crore per unit, on items such as utilities, clean rooms, testing laboratories and production equipment. Since March 2026 either a revised Schedule M or a WHO-GMP certificate can support the first claim.

Sources

Announced plans, figures and dates are as stated in the sources below at the time of publication and can change. Conclusions drawn from them are our reading.

  1. CDSCO: Gazette notifications (lists G.S.R. 922(E), G.S.R. 666(E), G.S.R. 127(E) and 2026 Drugs Rules notifications) (Accessed November 2026)
  2. CDSCO: G.S.R. 127(E), Drugs Amendment Rules, 2025, extension of timeline for implementation of Schedule M (PDF, 11 February 2025)
  3. CDSCO: G.S.R. 922(E), notification of revised Schedule M of the Drugs Rules, 1945 (PDF, 28 December 2023, English text read)
  4. CDSCO: Circulars (ONDLS extension filing, pharmacovigilance, WHO-GMP COPP, risk-based inspection guidelines) (Accessed November 2026)
  5. Lok Sabha: Unstarred Question 1162, answer of 9 February 2024 (risk-based inspections, Schedule M timelines) (PDF)
  6. Lok Sabha: Unstarred Question 864, answer of 29 November 2024 (GMP norms for small drug firms) (PDF)
  7. Lok Sabha: Unstarred Question 1892, answer of 6 December 2024 (RPTUAS) (PDF)
  8. Press Information Bureau, Ministry of Health and Family Welfare: Conditional extension of timeline to small and medium pharmaceutical manufacturers for compliance with revised Schedule M notification (12 February 2025)
  9. Press Information Bureau, Ministry of Health and Family Welfare: Steps taken to Prevent Sale of Adulterated Drugs (Rajya Sabha reply) (12 August 2025)
  10. Department of Pharmaceuticals: Corrigendum revamping the PTUAS sub-scheme (RPTUAS guidelines) (PDF, 11 March 2024)
  11. Department of Pharmaceuticals: Corrigendum modifying RPTUAS clauses (maximum raised to Rs 2 crore) (PDF, 17 September 2024)
  12. Department of Pharmaceuticals: Office memorandum modifying RPTUAS guidelines (certificates for instalments) (PDF, 21 March 2026)
  13. Indian Pharmaceutical Alliance: Update on Drugs and Cosmetics Act and Revised Schedule M, presentation by Chandrashekar Ranga, Joint Drugs Controller (India), CDSCO (PDF, 28 June 2024)
  14. PMDA (Japan): Summary presentation on India's revised Schedule M (PDF)
  15. JSA: Prism Healthcare, January 2024, Schedule M (PDF, law firm analysis)
  16. The Week (PTI): DCGI orders inspections of pharma units to ensure compliance with revised Schedule M norms (10 November 2025)
  17. The Week (PTI): 905 drug-manufacturing units inspected since 2022, action taken against 694, Govt to RS (22 July 2025)
  18. Reuters (via KFGO): India takes action against 90% of inspected high-risk pharmaceutical facilities, regulator says (30 July 2026)
  19. Business Standard: Over 8.5K MSME pharma units get 1-yr breather to adopt Schedule M standards (12 February 2025)
  20. Business Standard: CDSCO asks MSME pharma firms to apply online for Schedule M extension (March 2025)
  21. Business Standard: Health ministry unlikely to extend Schedule M GMP deadline for MSME pharma (29 December 2025; the 1,700 figure is unsourced in the article)
  22. Medical Dialogues: Health Ministry mulls extension for pharma firms to comply with revised Schedule M GMP norms (6 January 2026)
  23. Medical Dialogues: CDSCO, DoP told to find workable solution on revised Schedule M GMP concerns (19 January 2026)

The Healthcare Daily. We report from primary sources and list them on every story.

Read our editorial policy

The Handover

In a hospital, the handover is when one shift tells the next what changed and what to watch. Ours does the same for the business of healthcare, every weekday morning once it launches.

One email each weekday after launch. Unsubscribe at any time.

Search The Healthcare Daily

Saved stories

Kept in this browser only. There is no account and nothing is sent to us.